AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q9NPZ5

UPID:

B3GA2_HUMAN

Alternative names:

Beta-1,3-glucuronyltransferase 2; GlcAT-D; UDP-glucuronosyltransferase S

Alternative UPACC:

Q9NPZ5; Q5JS09; Q8TF38; Q96NK4

Background:

Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 2, also known as Beta-1,3-glucuronyltransferase 2, GlcAT-D, and UDP-glucuronosyltransferase S, plays a crucial role in the biosynthesis of L2/HNK-1 carbohydrate epitope on glycolipids and glycoproteins. This protein's activity is pivotal in the modification of cell surface molecules, influencing cell adhesion, migration, and interaction processes.

Therapeutic significance:

Understanding the role of Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 2 could open doors to potential therapeutic strategies. Its involvement in the biosynthesis of key carbohydrate epitopes suggests its potential impact on cellular communication and immune response, offering a promising avenue for research into novel drug targets.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.